{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:07:49Z","timestamp":1767175669047,"version":"build-2238731810"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1006335","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000}}],"reference-count":79,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009053","name":"DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/S\/14\/1\/501307"],"award-info":[{"award-number":["IA\/S\/14\/1\/501307"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1006335","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T13:27:56Z","timestamp":1531402076000},"page":"e1006335","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection"],"prefix":"10.1371","volume":"14","author":[{"given":"Vishnu","family":"Venugopal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranesh","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubesh","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9828","authenticated-orcid":true,"given":"Narendra M.","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e1004854","DOI":"10.1371\/journal.ppat.1004854","article-title":"Successes and challenges on the road to cure hepatitis C","volume":"11","author":"SM Horner","year":"2015","journal-title":"PLoS Pathog"},{"key":"ref2","article-title":"Guidelines for the screening care and treatment of persons with chronic hepatitis C infection","year":"2016"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2012.10.005","article-title":"Innate immunity and HCV","volume":"58","author":"MH Heim","year":"2013","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"NM Dixit","year":"2004","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/gutjnl-2012-303852","article-title":"Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C","volume":"63","author":"Y Rotman","year":"2014","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrgastro.2016.60","article-title":"Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights","volume":"13","author":"M Gotte","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance\u2013associated substitutions: State of the art summary","volume":"62","author":"E Lontok","year":"2015","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/v7122968","article-title":"Mechanisms of hepatitis c viral resistance to direct acting antivirals","volume":"7","author":"A Ahmed","year":"2015","journal-title":"Viruses"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"RM Ribeiro","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"L Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1128\/AAC.02068-13","article-title":"Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin","volume":"58","author":"E Murakami","year":"2014","journal-title":"Antimicrob Ag Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"C Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virol.2005.09.024","article-title":"The interferon response circuit: Induction and suppression by pathogenic viruses","volume":"344","author":"O Haller","year":"2006","journal-title":"Virology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","article-title":"Modelling hepatitis C therapy-predicting effects of treatment","volume":"12","author":"AS Perelson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1038\/ncomms4872","article-title":"Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment","volume":"5","author":"P Padmanabhan","year":"2014","journal-title":"Nat Commun"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e1000745","DOI":"10.1371\/journal.pcbi.1000745","article-title":"A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants","volume":"6","author":"BS Adiwijaya","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e1003772","DOI":"10.1371\/journal.pcbi.1003772","article-title":"Modeling viral evolutionary dynamics after telaprevir-based treatment","volume":"10","author":"EL Haseltine","year":"2014","journal-title":"PLoS Comput Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e1002339","DOI":"10.1371\/journal.pcbi.1002339","article-title":"A Viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection","volume":"8","author":"BS Adiwijaya","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"MH Powdrill","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s11538-012-9736-y","article-title":"Modeling Quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor","volume":"74","author":"L Rong","year":"2012","journal-title":"Bull Math Biol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"J Guedj","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e1003561","DOI":"10.1371\/journal.ppat.1003561","article-title":"Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle","volume":"9","author":"M Binder","year":"2013","journal-title":"PLoS Pathog"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/msb.2012.17","article-title":"Multi-layered stochasticity and paracrine signal propagation shape the type-I interferon response","volume":"8","author":"U Rand","year":"2012","journal-title":"Mol Sys Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/135965350601100303","article-title":"Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061","volume":"11","author":"E Herrmann","year":"2006","journal-title":"Antivir Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jhep.2016.02.022","article-title":"HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir","volume":"64","author":"H Dahari","year":"2016","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"JW Schoggins","year":"2011","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/hep.25908","article-title":"Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication","volume":"56","author":"P Metz","year":"2012","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.chom.2009.11.004","article-title":"Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation","volume":"6","author":"U Garaigorta","year":"2009","journal-title":"Cell Host Microbe"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/nm.4211","article-title":"Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling","volume":"22","author":"A Jarret","year":"2016","journal-title":"Nat Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"14799","DOI":"10.1073\/pnas.1618517114","article-title":"Pegylated IFN-alpha suppresses hepatitis C virus by promoting the DAPK-mTOR pathway","volume":"113","author":"WL Liu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1073\/pnas.1614623114","article-title":"Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein","volume":"114","author":"H Qi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1053\/j.gastro.2013.08.034","article-title":"Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver","volume":"145","author":"AJ Kandathil","year":"2013","journal-title":"Gastroenterology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3851\/IMP2974","article-title":"IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes","volume":"20","author":"F Kurbanov","year":"2015","journal-title":"Antivir Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0923-2516(96)82284-9","article-title":"Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV","volume":"147","author":"B Cribier","year":"1996","journal-title":"Res Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nrgastro.2012.101","article-title":"Genetics of IL28B and HCV-response to infection and treatment","volume":"9","author":"CN Hayes","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/nm.2892","article-title":"Antiretroviral dynamics determines HIV evolution and predicts therapy outcome","volume":"18","author":"DIS Rosenbloom","year":"2012","journal-title":"Nat Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jprot.2014.12.015","article-title":"A signature for immune response correlates with HCV treatment outcome in Caucasian subjects","volume":"116","author":"BJ Hare","year":"2015","journal-title":"J Proteomics"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/clpt.2010.35","article-title":"A comprehensive hepatitis C viral kinetic model explaining cure","volume":"87","author":"E Snoeck","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1574-6976.2011.00319.x","article-title":"Failure of innate and adaptive immune responses in controlling hepatitis C virus infection","volume":"36","author":"R Thimme","year":"2012","journal-title":"FEMS Microbiol Rev"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1128\/JVI.02824-12","article-title":"Response of hepatitis C virus to long-term passage in the presence of interferon-alpha. Multiple mutations and a common phenotype","volume":"87","author":"C Perales","year":"2013","journal-title":"J Virol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/hep.26770","article-title":"Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver","volume":"59","author":"S Wieland","year":"2013","journal-title":"Hepatology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2006.06.007","article-title":"Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States","volume":"131","author":"OV Nainan","year":"2006","journal-title":"Gastroenterology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"JM Micallef","year":"2006","journal-title":"J Viral Hep"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"C Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jcv.2009.09.029","article-title":"Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir","volume":"47","author":"F Suzuki","year":"2010","journal-title":"J Clin Virol"},{"key":"ref48","unstructured":"Vertex. Incivek highlights of prescribing information. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/pivrtxcom\/files\/uspi_telaprevirpdf\" xlink:type=\"simple\">http:\/\/pivrtxcom\/files\/uspi_telaprevirpdf<\/ext-link>. 2013."},{"key":"ref49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a \/ribavirin","volume":"43","author":"P Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/gutjnl-2013-306155","article-title":"Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C","volume":"64","author":"F Xiao","year":"2014","journal-title":"Gut"},{"key":"ref51","first-page":"445","article-title":"Modeling suggests a mechanism of synergy between hepatitis C virus entry inhibitors and drugs of other classes","volume":"4","author":"P Padmanabhan","year":"2015","journal-title":"CPT: Pharm Sys Pharm"},{"key":"ref52","article-title":"Submission to the United Nations Secretary-General\u2019s high-level panel on access to medicines","author":"G Alton","year":"2016","journal-title":"Gilead Sciences"},{"key":"ref53","unstructured":"UNITAID. Hepatitis C medicines: technology and market landscape\u2013update. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/wwwunitaideu\/images\/marketdynamics\/publications\/Hepatitis_C_Medicines_Technology_and_Market_Landscape__Updatepdf\" xlink:type=\"simple\">http:\/\/wwwunitaideu\/images\/marketdynamics\/publications\/Hepatitis_C_Medicines_Technology_and_Market_Landscape__Updatepdf<\/ext-link>. 2015."},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1073\/pnas.1610197114","article-title":"Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection","volume":"114","author":"Y Koizumi","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"E4527","DOI":"10.1073\/pnas.1705234114","article-title":"Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments","volume":"114","author":"H Ohashi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"E4524","DOI":"10.1073\/pnas.1704531114","article-title":"Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations","volume":"114","author":"P Padmanabhan","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2468-1253(16)30015-2","article-title":"Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study","volume":"1","author":"G Lau","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/j.gastro.2017.02.022","article-title":"Response-guided duration of direct acting antiviral therapy for chronic hepatitis C: Back to the future?","volume":"152","author":"A Aghemo","year":"2017","journal-title":"Gastroenterology"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","article-title":"Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study","volume":"385","author":"A Kohli","year":"2015","journal-title":"Lancet"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2016.04.006","article-title":"Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens","volume":"65","author":"B Maasoumy","year":"2016","journal-title":"J Hepatol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/jvh.12734","article-title":"No one size fits all\u2014shortening duration of therapy with direct acting antivirals for hepatitis C genotype 1 infection","volume":"24","author":"O El Sherif","year":"2017","journal-title":"J Viral Hepatitis"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.20232","article-title":"Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for na\u00efve patients infected with hepatitis C virus of genotype 1b and high viral load","volume":"75","author":"A Tsubota","year":"2005","journal-title":"J Med Virol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.hepres.2006.07.001","article-title":"First phase viral kinetic parameters and prediction of response to interferon alpha-2b\/ribavirin combination therapy in patients with chronic hepatitis C","volume":"36","author":"A Makiyama","year":"2006","journal-title":"Hepatol Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3851\/IMP2725","article-title":"Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling","volume":"19","author":"L Rong","year":"2014","journal-title":"Antivir Ther"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"S654","DOI":"10.1016\/S0168-8278(15)31045-X","article-title":"On-treatment viral kinetics do not predict SVR in patients with advanced liver disease receiving sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks","volume":"62","author":"C Hezode","year":"2015","journal-title":"J Hepatol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/apt.14478","article-title":"Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor","volume":"47","author":"S Fourati","year":"2018","journal-title":"Aliment Pharm Ther"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"ofu078","DOI":"10.1093\/ofid\/ofu078","article-title":"Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3\/4A-protease variants on the efficacy of boceprevir combined with peginterferon\/ribavirin","volume":"1","author":"JA Howe","year":"2014","journal-title":"Open Forum Inf Dis"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.25962","article-title":"Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial","volume":"56","author":"S De Meyer","year":"2012","journal-title":"Hepatology"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nature15711","article-title":"Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A","volume":"527","author":"J-H Sun","year":"2015","journal-title":"Nature"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1756283X16672392","article-title":"Prevalence of end of treatment RNA-positive\/sustained viral response in HCV patients treated with sofosbuvir combination therapies","volume":"10","author":"M Malespin","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"10233","DOI":"10.1038\/s41598-017-09776-z","article-title":"The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?","volume":"7","author":"THT Nguyen","year":"2017","journal-title":"Sci Rep"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.antiviral.2017.06.019","article-title":"Modeling HCV cure after an ultra-short duration of therapy with direct acting agents","volume":"144","author":"A Goyal","year":"2017","journal-title":"Antiviral Res"},{"key":"ref73","article-title":"Modelling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct\u2010acting antiviral agents","author":"S Baral","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"e1002307","DOI":"10.1371\/journal.pcbi.1002307","article-title":"Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry","volume":"7","author":"P Padmanabhan","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00002030-199805000-00006","article-title":"The frequency of resistant mutant virus before antiviral therapy","volume":"12","author":"RM Ribeiro","year":"1998","journal-title":"AIDS"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","article-title":"A methodology for performing global uncertainty and sensitivity analysis in systems biology","volume":"254","author":"S Marino","year":"2008","journal-title":"J Theor Biol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"e1004064","DOI":"10.1371\/journal.ppat.1004064","article-title":"A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity","volume":"10","author":"H Qi","year":"2014","journal-title":"PLoS Pathog"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"RA Fridell","year":"2011","journal-title":"Hepatology"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"RE Nettles","year":"2011","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1006335","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1006335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T06:31:05Z","timestamp":1661581865000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1006335"}},"subtitle":[],"editor":[{"given":"Roland R.","family":"Regoes","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":79,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1006335","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,12]]}}}